Exclusive Summary

• Isoprenaline Hydrochloride Injection is a classic emergency medication for bradycardia and bronchospasm, maintaining stable demand in global emergency and critical care settings.
• The product has passed consistency evaluation in China and features in-house API production, offering significant quality and cost advantages for global registration and competitiveness.
• Designated as an essential and easily short-supplied drug in China and included in the WHO Essential Medicines List, highlighting its critical global clinical status and unmet needs.
• As an established generic drug, it faces low patent barriers, offering numerous market entry opportunities, suitable for rapid international market expansion via Distribution.
• Its inclusion in China's Class A medical insurance underscores its economic viability and broad accessibility.

Asset Materials

Contact Us for Full Materials